Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07868835
PHASE3

Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)

Sponsor: Viking Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27kg/m2) adults with at least one weight-related comorbidity without type 2 diabetes mellitus.

Official title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants Without Type 2 Diabetes Mellitus Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

560

Start Date

2026-11

Completion Date

2028-08

Last Updated

2026-10-16

Healthy Volunteers

No

Conditions

Interventions

DRUG

VK2735

VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily

DRUG

Placebo comparator

Placebo comparator administered orally once daily